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Abstract 
Background: Model-based glycaemic control relies on sufficiency of underlying 
models to describe underlying patient physiology. In particular, very preterm infant 
glucose-insulin metabolism can differ significantly from adults, and is relatively 
unstudied.  In this study, C-peptide concentrations are used to develop insulin-
secretion models for the purposes of glycaemic control in neonatal intensive care. 
Methods: Plasma C-peptide, Insulin, and blood glucose concentrations (BGC)  were 
retrospectively analyzed from a cohort of 41 hyperglycemic very preterm (median 
age 27.2 [26.2 - 28.7] weeks) and very low birth-weight infants (median birth weight 
839 [735 – 1000] g). A 2-compartment model of C-peptide kinetics was used to 
estimate insulin secretion. Insulin secretion was examined with respect to nutritional 
intake, exogenous and plasma insulin concentration, and BGC. 
Results: Insulin secretion was found to be highly variable between patients and over 
time, and could not be modeled with respect to age, weight, or protein or dextrose 
intake. In 13 of 54 samples exogenous insulin was being administered, and insulin 
secretion was lower. However, low data numbers make this result inconclusive. 
Insulin secretion was found to increase with BG, with a stronger association in female 
infants than males (R2=0.51 vs. R2=0.13, and R2=0.26 for the combined cohort).  
Conclusions: A sex-based insulin secretion model was created and incorporated into 
a model-based glycemic control framework. Nutritional intake did not predict insulin 
secretion, indicating that insulin secretion is a complex function of a number of 
metabolic factors. 
 
Words: 240  
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1.0 Introduction 
Hyperglycemia (elevated blood glucose concentrations (BGC)) is a common 
complication of prematurity in very preterm (gestational age (GA) <32 weeks) infants 
[1 2], where stress and illness are compounded by immaturity of glucose-insulin 
physiology [3-5]. Hyperglycemia in very preterm babies has been associated with 
increased risk of morbidity and mortality [1 6 7], while hypoglycemia (low BGC) in 
preterm babies has also been associated with adverse neurodevelopment outcomes 
[8].  
There is currently no best practice method or target for glycemic control in preterm 
babies and BGC is often controlled by varying nutritional input [9]. Insulin therapy 
has been well established to improve glucose tolerance and increases post-natal 
weight gain (e.g. [10-13]). However, insulin treatment in preterm babies often results 
in excessive, iatrogenic, or protocol induced hypoglycemia [14 15]. Metabolic 
variability is a leading cause of this problem [16].  
STAR (Stochastic TARgeted) glycemic control is a decision support tool that uses a 
physiological model-based estimate of insulin sensitivity (SI) to describe a patient’s 
metabolic state with respect to insulin-glucose dynamics. STAR has proven safe and 
effective in adult intensive care [17 18], and a first iteration in the neonatal intensive 
care unit (NICU) has also shown promising results with tighter control and lower 
hypoglycemic incidence than other studies [19].  
STAR is a model-based system and thus relies, in part, on an accurate model of the 
glucose-insulin regulatory system to facilitate safe and accurate glycemic control. A 
key aspect of this modeling is endogenous secretion of insulin by the pancreas. Inter-
patient variability of endogenous insulin secretion can be a major cause of metabolic 
variability and difficulty in glycemic control.  In very low birth weight (VLBW) 
preterm infants, clinical limitations mean that pancreatic insulin secretion cannot be 
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quantified directly, and most studies indirectly assess insulin secretion through peak 
plasma insulin concentration.  
The aim of this study was to develop a model of insulin secretion in preterm neonates 
using a C-peptide kinetic model. An accurate model of neonatal insulin secretion will 
then be used to improve the current glucose-insulin physiological models used by 
STAR in the NICU. These results build upon previous results examining the effect of 
discrete (e.g. sex, ethnicity, singleton vs. multiple births) and clinical (e.g. CRIB2 
score) factors on insulin secretion in preterm neonates [20].   
2.0 Methods    
 
2.1 Patient Cohort 
The cohort and C-Peptide analysis have been described elsewhere in full [15 20]. In 
brief: retrospective analysis was carried out on plasma samples collected during a 
randomized control trial of glycemic control (The HINT trial [15], Australian Clinical 
Trials Registry 12606000270516, ethics approval from Northern X ethics committee). 
Hyperglycemic (two BGC measures >153 mg/dL more than 4 hours apart) very 
preterm (GA < 32 weeks, or birth weight <1500g) neonates were assigned to tight 
glycemic control (TGC, target BGC range 72-108 mg/dL) or standard care at 
National Women’s Health NICU, Auckland City Hospital, New Zealand [15]. 
BGC, insulin infusions, and daily nutritional intake were recorded.  Blood samples 
were taken to determine plasma insulin (Azsym system auto-analyzer, Abbott 
Laboratories, Abbott Park, IL) and BGC (glucose oxidise method, ABL 700, 
Radiometer Ltd, Copenhagen, Denmark) for each infant at randomization, 7 and 14 
days after randomization, and at GA=36 weeks. Remaining plasma samples were 
frozen. 
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Retrospective C-peptide analysis (immunometric assays, Elecsys 2010, Roche 
Diagnostics, Germany) was carried out on some of the frozen samples if there was 
sufficient remaining blood from samples taken 0-15 days after randomization, and if 
infant had GA<32 weeks. Cohort characteristics are given in Table 1.  
Table 1: Sample cohort patient characteristics 
Characteristic Value 
 Total patients 41 
      Control group 21 
      Tight Glycemic Control group 20 
 Male (%) 20 (49%) 
 Multiple Birth 11 (27%) 
 Antenatal steroid exposure 39 (95%) 
 Maternal diabetes 1 (2%) 
Age  
 Gestational, weeks 27.2 [26.2 - 28.7] 
 Post natal age, days 9.5 [4 -17] 
Birth weight  
 grams 839 [735 – 1000] 
 Z score -0.19[-1.03 - 0.14] 
 Small for gestational age 6 (15%) 
 CRIB 2 score 12 [10-14] 
Ethnicity  
 Asian 9 (22%) 
 Caucasian 11 (27%) 
 Maori 17 (41%) 
 Pacific Island 4 (10%) 
Sample data  
 Number of Samples 54 
 Day after randomization  7 [0 - 14] 
 BGC, mg/dL 135 [92 – 189] 
 Plasma insulin concentration, mU/L 59.0  [99.3 – 181.9] 
 Plasma C-peptide concentration, nmol/L 2.3 [1.1 - 4.2] 
 Cortisol at randomization, μg/dL 10.1 [9.1-15.1] 
Numbers are presented as median [IQR] or number (% of total). CRIB 2: Clinical 
Risk Index for Babies.  
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2.2 Model Equations of C-peptide kinetics 
C-peptide is secreted in equimolar quantities with insulin, and is predominantly 
cleared by the kidney. In comparison, insulin is cleared by liver and peripheral tissues 
in a highly variable manner, as well as through the kidneys. Therefore, the relatively 
simple kinetics of C-peptide provide a better means to estimate insulin secretion [21]. 
A 2 compartment kinetics model [21] is used to describe the concentration of C-
peptide in the central compartment of plasma, C, and peripheral extra vascular 
compartment, Y: 
𝑑𝐶
𝑑𝑡
= 𝑆 − (𝑘1 +  𝑘3)𝐶 + 𝑘2𝑌 (1) 
𝑑𝑌
𝑑𝑡
= 𝑘1𝐶 − 𝑘2𝑌 (2) 
 
The rate of C-peptide (and insulin) secretion is S, and transport of C-peptide from the 
central to the peripheral compartment, and vice versa, is described by k1 and k2. The 
parameter k3  describes the irreversible renal clearance of C-peptide from the central 
compartment via the kidney [21].  
Sampling constraints due to limited blood volume in this cohort (~50 mL/kg, [22]) 
mean frequent, serial measurements of C-peptide were not physically or ethically 
possible. Assuming steady-state, it follows from Equation 2 that the rate of C-peptide 
entering and leaving the peripheral compartment must be equal. Hence, substituting 
this equality into Equation 1 and rearranging yields:  
𝑆 =  𝑘3𝐶 (3) 
 
Since insulin is secreted in equimolar quantities with C-peptide, under steady state 
conditions the rate of secretion of insulin is directly proportional to the measured 
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concentration of C-peptide in the central compartment. In infants fed via constant IV 
infusion, this steady state assumption is reasonable. 
Since no studies have been performed in preterm or term neonates to determine C-
peptide kinetics, adult data and methodology [21 23] were used as an approximation 
given that the functionality is also no different. A short half life of 4.95 min and a 
fraction, F, of 0.96 was used based on non-obese or diabetic adult data [21]. The long 
half life thus was calculated using [21]: 
long-half life (min)= 0.14*age (years) + 29.2. (4) 
To give an estimated long half-life of 29.2 minutes for newborns [23]. The kinetic 
parameters were then individually calculated using these cohort specific values, as 
per [21]: 
𝑘2 =  𝐹 (𝑏 − 𝑎) +  𝑎 (5) 
𝑘3 =  
𝑎 𝑏
𝑘2
 (6) 
𝑘1 =  𝑎 +  𝑏 −  𝑘2 − 𝑘3 (7) 
Where a = log(2)/(short half life), and b = log(2)/(long half life). The resulting 
calculated value for 𝑘3 for all neonates was 𝑘3 = 0.0644 min
-1, which is within the 
reported normal clearance rates in Table 2. 
Table 2: C-peptide kinetic parameters in adults [21 24 25] 
 
Patient 
Cohort 
k1 [1/min] k2 [1/min] k3 [1/min] 
 Eaton et 
al, 1980 
Normal 
n=20 
0.047 
± 0.002 
0.035 
± 0.002 
0.049 
± 0.001 
Van Cauter 
et al, 1992 
Normal 
n=111 
0.053 
± 0.002 
0.051 
± 0.001 
0.062 
± 0.001 
Obese 
n=53 
0.067 
± 0.003 
0.051 
± 0.002 
0.065 
± 0.013 
Polonsky 
et al, 1986 
Normal 
n=10 
0.057 
± 0.006 
0.054 
± 0.006 
0.06 
± 0.002 
Diabetic 
n=7 
0.037 
± 0.004 
0.031 
± 0.004 
0.057 
± 0.002 
 All values are mean ± SEM, 
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2.3 Trend analysis 
Endogenous insulin secretion was calculated using Equations 3 – 7. Results were 
analyzed with respect to patient birth weight, GA, dextrose and protein intake, 
nutritional delivery method, plasma insulin and BGC, and patient sex, to determine 
strong predictors of insulin secretion within this cohort.  
2.4 Statistical Analysis 
Results are presented as median with interquartile range (IQR). Non parametric data 
were analyzed by the Mann-Whitney U-test, and the Kruskal-Wallis test, which 
extends the Mann-Whitney U-test to more than 2 samples. Correlations were 
calculated using a linear least squares regression analysis, and p-values are given with 
respect to the null hypothesis that the slope of the linear regression is 0.  Statistical 
power of subgroup results analysis is calculated using the method of [26] applied to 
log-normalized insulin secretion values. Multiple linear regression across a range of 
variables, such as GA, weight, postnatal age, and BGC, was used to generate more 
complex models.  
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3.0 Results 
 
 
Birth weight or GA and insulin secretion were not strongly correlated (Figure 1, 
R2≤0.07), but endogenous insulin secretion did decrease with increasing weight 
and/or gestational age (p≤0.06). However, trends with post-natal age are confounded 
by the fact that there was significantly higher BGC at randomization than 7-14 days 
post-randomization (99 [81–125] vs. 191 [164–229] mg/dL, p<0.005).  
 
Neither daily protein nor dextrose intake was significantly correlated with insulin 
secretion (Figure 2). Adjusting for BGC at the time of the sample did not affect this 
result, with high and low protein intakes being equally scattered with respect to blood 
glucose and insulin secretion rate. Insulin secretion could not be modeled based on 
nutritional intake. 
 
 
Figure 1: Insulin secretion is highly variable with birth weight.  
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a) b) 
  
c) d) 
Figure 2: Endogenous insulin secretion and blood glucose concentration (BGC) 
with respect to protein (a & b) and total dextrose intake (c & d) on the day the 
sample was taken. In parts a) and c) data points are scaled in size by the 
magnitude of nutritional intake, with data points from infants with a larger mass 
of intake being larger in size. 
In 13 babies there was an exogenous insulin infusion at the time of the C-peptide 
sample. Figure 3 shows lower insulin secretion in the presence of exogenous insulin, 
(3.7 [1.8-6.9] vs. 9.8[4.7-17.8] mU.kg-1.min-1, p=0.02, statistical power 90%). There 
was a positive relationship between plasma insulin concentration and insulin 
secretion, as shown in Figure 3b, but this is heavily influenced by a relative few 
measures towards the upper end of the data range. There was no clear relationship 
between both BGC and plasma insulin with insulin secretion (Figure 2a). While there 
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is evidence of suppression of insulin secretion with exogenous insulin, data is 
insufficient to build further models. 
  
a) b) 
 Figure 3: Endogenous insulin secretion with a) blood glucose concentration 
(BGC) and plasma insulin concentration, and b) plasma insulin. In parts a) data 
points are scaled in size by the magnitude of plasma insulin, with larger data 
points representing samples with higher plasma insulin concentration. Open (o) 
and closed (●) circles denote results from infants not receiving and receiving 
exogenous insulin at the time of sampling respectively.  
There was a weak relationship between insulin secretion and BGC (Figure 4), which 
was stronger in females than males.  It has been previously reported that the 
difference between the sexes in insulin secretion was true over the entire BGC range 
(p<0.005, statistical power >95%) with no statistically significant difference between 
clinical characteristics (p ≥ 0.17), plasma insulin concentration (p=0.30), or nutrition 
regimes (p ≥ 0.34) [20]. Figure 4 also shows separate male and female models for 
BGC dependant secretion in these cohorts, as well as an overall cohort method. 
Insulin secretion as a function of sex and BGC is defined: 
𝑢𝑒𝑛 =  {
max(4.2, −1.5 + 0.106 ∗ 𝐵𝐺𝐶)   
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The 95% confidence interval for the intercept and slope were (-7.9, 4.9) and (0.061, 
0.150) respectively for the female subcohort, and (-8.0, 8.0) and (-0.150, 0.206) 
respectively  for the male subcohort. The whole cohort model in Figure 4 is defined: 
𝑈𝑒𝑛 = max (3.3, −1.3 + 127.0 ∗ 𝐵𝐺𝐶) (9) 
The 95% confidence interval for the intercept and slope of the whole cohort model 
was (-7.2, 4.6) and (-0.046, 0.132). 
Multiple linear regression models which accounted for combinations of GA, weight, 
postnatal age, BGC, dextrose intake and exogenous insulin were not able to predict 
insulin secretion (R2 ≤ 0.2). 
Figure 4: Models of endogenous insulin secretion as a function of blood glucose 
concentration (BGC) over the whole cohort and male and female sub cohorts. A 
total of 5 data points from 54 total (9%) were excluded from the analysis as 
outliers based on a 2-3 fold difference with other data points of similar BGC. Of 
these data points, 3/5 were from heavier and older patients of GA>29 weeks. 
However, 2 were from male and female babies with a GA of 26 weeks’. 
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4.0 Discussion 
In the past insulin secretion in preterm infants has been indirectly analyzed using 
peak plasma insulin concentration. In contrast, this study assesses insulin secretion 
using C-peptide concentrations, which is a more accurate predictor insulin secretion 
due to its simpler and less variable clearance kinetics. From this data, models of 
insulin secretion were built.  
Insulin secretion was found to increase with increasing BGC, a result reported 
previously in infant and adult dogs [27]. In preterm infants,  a reduction in plasma 
glucose concentration in hyperglycemic preterm infants has been observed to be  
accompanied by a reduction in insulin secretion [5]. This result matches expected 
physiology, where GLUT2 transporters in pancreatic beta cells enable sensitivity to 
changes in BGC [28].   
Sensitivity of insulin secretion to BGC was higher in females. This result is consistent 
with previous work showing overall higher insulin secretion in female preterm 
infants, independent of a number of clinical factors [20]. Insulin secretion was similar 
between males and females at the lower end of the basal blood glucose range, but the 
linear model fitted to the female sub cohort had a larger slope, indicating heightened 
pancreatic response to changes in BGC. This result perhaps suggests that the males 
were sicker or had higher C-peptide clearance.  Higher insulin secretion in the 
females at comparable plasma insulin concentrations could also indicate higher 
insulin clearances. However, glomerular filtration rate has not been observed to differ 
with sex previously [29]. Insulin secretion and glycemic differences between the 
sexes in later life is more fully discussed elsewhere [20]. 
No differentiation of insulin secretion rates was seen between differing levels of 
protein or glucose intake in the neonates. This result is unexpected as an increase in 
plasma insulin concentrations in response to a glucose stimulus [30-34], amino acids 
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such as theophylline [32 35-38], and glucose priming [30] has been previously been 
observed in preterm infants. This discrepancy could be a result of differing study 
methodology and the more direct approach to estimating insulin secretion taken here. 
It could also be a result of nutrition records reflecting daily totals only, or reflect the 
differing physiological stress and degree of prematurity. The latter is regarded as 
more likely, as nutrition infusions or feeds are usually kept relatively constant 
throughout the day. Previous work analyzed differences between feeding methods, 
and found no difference in insulin secretion with method or bias by infant sex 
distribution between groups [20]. In contrast to previous studies, this cohort is 
hyperglycemic, and thus more likely to have an underlying condition. In this study, 
some neonates showed high insulin secretion rates with relatively higher protein 
intakes (3-5g/kg/day), as would be expected. In those that did not behave as expected, 
it is possible that if a pancreas is compromised due to prematurity, or for any reason, 
then the presence of protein is unlikely to affect endogenous insulin secretion.  
There was a positive correlation between endogenous insulin secretion and plasma 
insulin. Infants in this post-hoc analysis were evenly distributed between control and 
TGC cohorts in the original HINT study [15]. Male and female infants were evenly 
spread between the exogenous insulin and no exogenous insulin groups, indicating 
sex was not responsible for this difference, and vice versa. These data points are 
tightly clustered with respect to BGC, and are thus heavily influenced by one or two 
points at extremes in BGC. In addition, endogenous insulin secretion was not further 
suppressed in the presence of increasing exogenous insulin infusion, as might be 
expected. 
The regulation of blood glucose is complex and involves both the liver and the 
pancreas. Unfortunately, it was not possible to describe the contribution of the liver to 
glycemic regulation in this study. In adults, insulin secretion by the pancreas is 
regulated by plasma insulin and BGC, as well as hormones such as glucagon, cortisol, 
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and adrenaline [39-41]. Stress can also affect secretion [42], generally through these 
aforementioned hormones. Previous work did not find trends between insulin 
secretion and GA, randomization, singleton vs. multiple birth, ethnicity, plasma 
cortisol, pre-natal steroid exposure, or nutrition delivery type [20]. Multiple linear 
regression using GA, weight, postnatal age, nutritional intake, exogenous insulin, and 
BGC as predictor variables did not significantly alter insulin secretion predictability. 
The individual effect of each of these factors is impossible to isolate, and very 
complicated models that could not be specified easily at the bedside, if at all, would 
be required to successfully model insulin secretion to a high degree of accuracy. 
Much of the variability observed in this data can probably be attributed to stress, 
differing patient conditions, and the effect of hormone signaling on the steady state 
assumption. In addition, data available was insufficient to give an indication of 
insulin secretion between morbidity groups in the cohort.   
The major assumption of this research is that of steady state C-peptide kinetics. This 
assumption was driven by necessity, as the very low blood volume of very premature 
neonates (~ 50 mL/kg, [22])  means serial sampling of blood over time periods 
necessary to capture metabolic dynamics is not ethically and practically possible 
[43], particularly given the large percentage of total blood volume that would be 
required.. However, while this assumption may be necessary, it does not inevitably 
follow that it is entirely inaccurate.  
C-peptide dynamics are predominantly a function of insulin (and C-peptide) secretion 
and kidney clearance. Insulin secretion is known to be affected by a number of 
factors, which are predominantly nutritional. Steady state is therefore a reasonable 
assumption in premature infants who receive their nutrition intravenously. While this 
assumption is theoretically less reasonable in enterally fed infants, no significant 
difference in insulin secretion  was found between enterally and parenterally fed 
infants (p=0.59), and the sex based difference in insulin secretion held if only 
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parenterally fed infants were considered [20]. This perhaps suggests that enteral 
nutrition administration times (~5-30min depending on delivery method and patient 
condition) are long enough, and/or feeds are administered frequently enough, to 
approximate steady state administration, or that there was little effect on insulin 
secretion due to immaturity in gut function, hormonal signaling, or metabolism. 
Renal clearance rates are affected by gestational age and weight [44], medication, and 
illness and injury such as sepsis and intra-ventricular hemorrhage [45]. Differences in 
renal clearance of C-peptide may account for some of the inter-patient variability in 
insulin secretion results, but is unlikely to affect the assumption of steady state, 
particularly given constant nutrition inputs. The insulin secretion model developed is 
a population model and reflects a generalized response across the cohort. As 
previously mentioned, glomerular filtration rate has not been previously observed to 
differ with sex [29]. 
Finally, while there is the potential that some glucose-insulin flux was occurring in 
any given infant, across the cohorts used there are enough subjects to assure that the 
central tendency holds. Thus, the snapshot of data obtained would be random in 
regard to a given net tendency or flux. Hence, since the model is based on cohort 
trends, the central tendency should hold around this assumption. 
Adult C-peptide kinetic parameters, adjusted for age, were used because of the 
inability to comprehensively derive parameters for the neonatal cohort. If the 
resulting insulin secretion is also calculated using k3 kinetic values that are 
approximately 2 standard deviations (k3 = [0.05, 0.07]) from the normal kinetics 
reported in Table 2, then the insulin secretion could be in error by up to ~20%. In 
addition, it is not possible in this cohort to determine patient specific C-peptide 
kinetic parameter values.  For the purposes of model based control, the k3 parameter 
used is thus sufficient, and changes to this parameters does not change any of the 
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results or trends observed, but only shift these trends. In addition, in terms of outputs 
from the control protocol, any scale inaccuracies are absorbed and scale the time 
varying patient-specific insulin sensitivity parameter [46]. In model based control, it 
is the insulin secretion dynamic shape, more than the value (assuming it is within a 
reasonable rang of the true value), that is important, so scale inaccuracies will not 
significantly affect control outputs.    
This study has been carried out in the context of model-based control. While samples 
were taken from both arms of a glycemic control trial and reflect a range of different 
clinical intervention histories, it is believed that this cohort adequately describes 
likely candidates for glycemic control and thus the results provide new insights from 
data that is only rarely available.  A total of 54 samples is greater than the 51 samples 
required for a regression analysis with a single independent variable [47]. As a result 
of this study, a sex and BGC based model for insulin secretion in preterm infants was 
created. 
5.0 Conclusions 
Insulin secretion was estimated from C-peptide concentrations and used to generate a 
model for use in model-based glycemic control. Blood glucose concentration and sex 
were found to be the strongest predictors for insulin secretion, with females having 
higher insulin secretion and a more consistent increase with blood glucose 
concentration. Insulin secretion was observed to be lower in the presence of 
exogenous insulin, but data was insufficient to be conclusive. Insulin secretion was 
not found to be highly correlated with glucose or protein intake. Insulin secretion in 
preterm neonates is a complex function of a number of factors, and high variability is 
seen between patients of a similar gestational age and weight.  
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